Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients

被引:0
|
作者
Douglas, TH
Morgan, TO
McLeod, DG
Moul, JW
Murphy, GP
Barren, R
Sesterhenn, IA
Mostofi, FK
机构
[1] WALTER REED ARMY MED CTR, DEPT SURG, UROL SERV, WASHINGTON, DC 20307 USA
[2] WALTER REED ARMY MED CTR, DEPT CLIN INVEST, WASHINGTON, DC 20307 USA
[3] UNIFORMED SERV UNIV HLTH SCI, DEPT SURG, CTR PROSTATE DIS RES, BETHESDA, MD 20814 USA
[4] PACIFIC NW CANC FDN, CANC RES DIV, SEATTLE, WA USA
[5] ARMED FORCES INST PATHOL, DEPT GENITOURINARY PATHOL, WASHINGTON, DC 20306 USA
关键词
prostate specific antigen; prostate specific membrane antigen; free prostate specific antigen; prostate carcinoma; radical prostatectomy;
D O I
10.1002/(SICI)1097-0142(19970701)80:1<107::AID-CNCR14>3.0.CO;2-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND, Higher preoperative prostate specific antigen (PSA) levels are associated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA) elevations were associated with clinical progression and hormone-refractory carcinoma. The goal of this study was to evaluate the serum markers PSMA, free PSA (FPSA), free:total PSA ratio (F:TPSA), and total PSA (PSA) in men undergoing RP. METHODS, Serum was obtained from 63 patients undergoing RP for clinically localized (Tlc, T2) prostate carcinoma. Serum PSA and FPSA were determined by Hybritech Tandem-E-R and Tandem-R-R, respectively, and PSMA was determined by Western blot analysis. Serum values for these markers were compared with the patho logic stage, surgical margin status, Gleason sum, prostate size (as calculated via reconstruction and transrectal ultrasound), tumor size based on pathologic assessment of the whole mount, and World Health Organization (WHO) grade of the prostatectomy specimen. Markers were also compared against demographic information and the patients' age and race. RESULTS. There was a weak correlation between serum PSA and positive surgical margins, higher Gleason sum, and WHO grade (P < 0.05). Receiver operating characteristic curve (ROC) analysis comparing sensitivity and specificity of the markers to positive and negative margins as well as seminal vesicle invasion demonstrated PSA and FPSA predictive ability for seminal vesicle invasion. The area under the curve for PSA and FPSA in this case was 0.7318 and 0.7432, respectively. There was also a weak correlation between the FPSA level and margins, with a low ROC area under the curve of 0.6789. The FPSA cannot distinguish the more advanced stage of disease. There was no significant correlation between F:TPSA and PSMA with regard to the study variables in predicting organ confinement. High PSMA levels only correlated with higher stage and were maximal in pT4a classified disease. CONCLUSIONS. Higher PSA and FPSA levels are likely to be associated with more locally advanced disease. Total PSA was the best marker. However, the cutoff values necessary for significant accuracy between PSA and FPSA are not of clinical usefulness due to the lack of specificity and sensitivity of the markers at those cutoffs. F:TPSA and PSMA levels as currently measured are of limited value in discriminating more aggressive disease in patients with clinically localized CaP. (C) 1997 American Cancer Society.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 50 条
  • [31] Colonoscopy effects on serum prostate specific antigen levels
    Barbatzas, C.
    Dellis, A.
    Grivas, I.
    Trakas, N.
    Ekonomou, A.
    Kostakopoulos, A.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2004, 36 (02) : 203 - 206
  • [32] Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml
    Morote, J
    Raventos, CX
    Lorente, JA
    LopezPacios, MA
    Encabo, G
    deTorres, I
    Andreu, J
    JOURNAL OF UROLOGY, 1997, 158 (02) : 502 - 504
  • [33] Prostate-specific membrane antigen
    Fair, WR
    Israeli, RS
    Heston, WDW
    PROSTATE, 1997, 32 (02) : 140 - 148
  • [34] Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Weinstein, M
    Tomaszewski, JE
    Schultz, D
    Rhude, M
    Rocha, S
    Wein, A
    Richie, JP
    JOURNAL OF UROLOGY, 2001, 166 (06) : 2185 - 2188
  • [35] Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer
    Bottke, D
    Wiegel, T
    Höcht, S
    Müller, M
    Schostak, M
    Hinkelbein, W
    ONCOLOGY, 2003, 65 : 18 - 23
  • [36] Serum levels of prostate specific antigen in men on hemodialysis
    Wolff, JM
    Ting, O
    Borchers, H
    Rohde, D
    Jakse, G
    ANTICANCER RESEARCH, 2000, 20 (6D) : 5191 - 5193
  • [37] Colonoscopy effects on serum prostate specific antigen levels
    C. Barbatzas
    A. Dellis
    I. Grivas
    N. Trakas
    A. Ekonomou
    A. Kostakopoulos
    International Urology and Nephrology, 2004, 36 : 203 - 206
  • [38] Serum levels of total and free prostate specific antigen in men on hemodialysis
    Sasagawa, I
    Kubota, Y
    Hayami, S
    Adachi, M
    Nakada, T
    Miura, H
    Imai, K
    JOURNAL OF UROLOGY, 1998, 160 (01) : 83 - 85
  • [39] Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia
    Furuya, Y
    Akakura, K
    Tobe, T
    Ichikawa, T
    Igarashi, T
    Ito, H
    INTERNATIONAL JOURNAL OF UROLOGY, 2000, 7 (12) : 447 - 451
  • [40] Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: Results from the search data base
    Freedland, SJ
    Kane, CJ
    Presti, JC
    Terris, MK
    Amling, CL
    Dorey, F
    Aronson, WJ
    JOURNAL OF UROLOGY, 2003, 169 (03) : 969 - 973